About the study: In this cross-sectional study of 60 new therapeutic agents approved by the Food and Drug Administration from 2009 to 2018, there was no association between estimated research and development investments and treatment costs based on list prices at product launch. or on the basis of net prices. price one year after launch. The results of this study suggest that pharmaceutical companies should make additional data available if they want to use this argument to justify high prices.
Authors: Olivier J. Wouters, Ph.D., of the London School of Economics and Political Science, is the corresponding author.
To access the study under embargo: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s note: Please see the article for more information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers with free access to the full-text article This link will be live at time of embargo http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.18623?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092622
About Open JAMA Network: Open JAMA Network is the new online-only open access general medical journal of the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health fields. Each article is put online for free from the day of its publication.
Open JAMA Network
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.